FDA OKs New Drug for Lung Cancer With c-Met Overexpression

(MedPage Today) -- The FDA granted accelerated approval to telisotuzumab vedotin (Emrelis) for the treatment of adults with previously treated, locally advanced, or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein...